This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ROSENFELD, R. G. Articles by HINTZ, R. L. Search for Related Content PubMed PubMed Citation Articles by ROSENFELD, R. G. Articles by HINTZ, R. L.

Both Human Pituitary Growth Hormone and Recombinant DNA-Derived Human Growth Hormone Cause Insulin Resistance at a Postreceptor Site^*

RON G. ROSENFELD, DARRELL M. WILSON, LAURA A. DOLLAR, ANN BENNETT and RAYMOND L. HINTZ

Department of Pediatrics, Stanford University Medical Center Stanford, California 94305

We have investigated the effects on carbohydrate metabolism of human GH produced by recombinant DNA technology (methionyl-hGH) compared with pituitary hGH, Twelve normal adult male subjects received four daily im injections of either methionyl-hGH or pituitary hGH in a double blind, crossover study. Oral glucose tolerance tests and assays of insulin binding to peripheral monocytes were performed before the initial administration and 12 h after the fourth injection of both hGH preparations.

Both methionyl-hGH and pituitary hGH resulted in significant carbohydrate intolerance, with a rise in fasting plasma glucose from 96.6 ± 2.9 to 105.9 ± 3.0 mg/ml (mean ± SEM) after pituitary hGH and from 96.2 ± 1.5 to 107.5 ± 3.3 mg/dl after methionyl-hGH (P < 0.01). The area under the glucose tolerance curve increased by 34% after pituitary hGH and by 37% after methionyl-hGH. With both hGH preparations, carbohydrate intolerance was associated with marked hyperinsulinemia, with a rise in fasting plasma insulin levels from 9.4 ± 1.2 to 33.2 ± 7.8 µU/ml after pituitary hGH and from 7.4 ± 1.1 to 45.8 ± 11.1 µU/ml after methionyl-hGH (P < 0.01). The integrated plasma insulin levels during the oral glucose tolerance test tripled after both hGH preparations.

The pronounced insulin resistance could not be attributed to an alteration in insulin receptor concentrations. Both hGH preparations were associated with small reductions in insulin binding o t monocytes at tracer concentrations, but the decline in binding was not statistically significant. The calculated binding sites per cell and Kë were not significantly altered by hGH administration.

We conclude that methionyl-hGH and pituitary hGH are indistinguishable in their ability to induce insulin-resistant carbohydrate intolerance. This decrease in insulin sensitivity cannot be attributed to an alteration in insulin binding, and presumably represents a postreceptor defect in insulin action. (J Clin En-docrinol Metab 54: 1033, 1982)

^* This work was supported by NIH Grants AM-28229, AM-21058, and AM-24085.

To whom requests for reprints should be addressed.

Received October 1, 1981.

This article has been cited by other articles:

				A. Colao, R. S. Auriemma, M. Galdiero, P. Cappabianca, L. M. Cavallo, F. Esposito, L. F. S. Grasso, G. Lombardi, and R. Pivonello Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 528 - 537. [Abstract] [Full Text] [PDF]

				L. Audi, A. Carrascosa, C. Esteban, M. Fernandez-Cancio, P. Andaluz, D. Yeste, R. Espadero, M. L. Granada, H. Wollmann, L. Fryklund, et al. The exon 3-deleted/full-length Growth Hormone Receptor Polymorphism Does Not Influence the Effect of Puberty or Growth Hormone Therapy on Glucose Homeostasis in Short Non-Growth Hormone-Deficient Small-for-Gestational-Age Children: Results from a Two-Year Controlled Prospective Study J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2709 - 2715. [Abstract] [Full Text] [PDF]

				C. Nielsen, L. C. Gormsen, N. Jessen, S. B. Pedersen, N. Moller, S. Lund, and J. O. L. Jorgensen Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2842 - 2850. [Abstract] [Full Text] [PDF]

				S. A. Kaplan and P. Cohen REVIEW: The Somatomedin Hypothesis 2007: 50 Years Later J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4529 - 4535. [Abstract] [Full Text] [PDF]

				E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both? Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244. [Abstract] [PDF]

				H Biering, B Saller, J Bauditz, M Pirlich, B Rudolph, A Johne, M Buchfelder, K Mann, M Droste, I Schreiber, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis Eur. J. Endocrinol., February 1, 2006; 154(2): 213 - 220. [Abstract] [Full Text] [PDF]

				C. A. Hurty and B. Flatland Feline Acromegaly: A Review of the Syndrome J. Am. Anim. Hosp. Assoc., September 1, 2005; 41(5): 292 - 297. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]

				K. H. W. Lange, B. Larsson, A. Flyvbjerg, R. Dall, M. Bennekou, M. H. Rasmussen, H. Orskov, and M. Kjaer Acute Growth Hormone Administration Causes Exaggerated Increases in Plasma Lactate and Glycerol during Moderate to High Intensity Bicycling in Trained Young Men J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4966 - 4975. [Abstract] [Full Text] [PDF]

				K. Yuen, K. Ong, S. Husbands, P. Chatelain, L. Fryklund, P. Gluckman, M. Ranke, D. Cook, R. Rosenfeld, J. Wass, et al. The Effects of Short-Term Administration of Two Low Doses Versus the Standard GH Replacement Dose on Insulin Sensitivity and Fasting Glucose Levels in Young Healthy Adults J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1989 - 1995. [Abstract] [Full Text] [PDF]

				C. Parkinson, W. M. Drake, M. E. Roberts, K. Meeran, G. M. Besser, and P. J. Trainer A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed Meal J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1797 - 1804. [Abstract] [Full Text] [PDF]

				F. P. Dominici and D. Turyn Growth Hormone-Induced Alterations in the Insulin-Signaling System Experimental Biology and Medicine, March 1, 2002; 227(3): 149 - 157. [Abstract] [Full Text] [PDF]

				D. Le Roith, C. Bondy, S. Yakar, J.-L. Liu, and A. Butler The Somatomedin Hypothesis: 2001 Endocr. Rev., February 1, 2001; 22(1): 53 - 74. [Abstract] [Full Text]

				S. Molon-Noblot, P. Laroque, S. Prahalada, L. G. Stabinski, C. P. Peter, P. Duprat, and M. J. Van Zwieten Morphological Changes in the Kidney of Dogs Chronically Exposed to Exogenous Growth Hormone Toxicol Pathol, July 1, 2000; 28(4): 510 - 517. [Abstract] [PDF]

				H. Nørrelund, N. Vahl, A. Juul, N. Møller, K. G. M. M. Alberti, N. E. Skakkebæk, J. S. Christiansen, and J. O. L. Jørgensen Continuation of Growth Hormone (GH) Therapy in GH-Deficient Patients during Transition from Childhood to Adulthood: Impact on Insulin Sensitivity and Substrate Metabolism J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1912 - 1917. [Abstract] [Full Text]

				S. D. Frasier, C. R. Rudlin, H. J. Zeisel, H. H. Liu, P. C. Long, B. Senior, D. N. Finegold, B. B. Bercu, J. F. Marks, and G. P. Redmond Effect of Somatotropin of Mammalian Cell Origin in Growth Hormone Deficiency Arch Pediatr Adolesc Med, May 1, 1992; 146(5): 582 - 587. [Abstract] [PDF]